Dechra Pharmaceuticals PLC — Director's Dealing 2014

Sep 12, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5863R

Dechra Pharmaceuticals PLC

12 September 2014

12 September 2014

Dechra® Pharmaceuticals PLC

(Dechra or the Company)

Director / PDMR shareholding

Exercise of LTIP options:

Dechra Pharmaceuticals PLC announces that on 11 September 2014, the following Director and PDMR exercised nil cost options over ordinary shares of 1p each in the Company. The options were granted to them on 7 September 2011 pursuant to the Dechra Pharmaceuticals PLC Long Term Incentive Plan (the LTIP).

Both Ian Page and Zoe Goulding have sold sufficient shares (acquired pursuant to the LTIP exercise) in order to fund the resulting tax liability.  

Name	Capacity	Options Exercised	Shares Sold	Sale Price per share	Total beneficial shareholding following this announcement	Percentage of issued share capital
Ian Page	Director	92,811	43,753	£7.625	955,701	1.088%
Zoe Goulding	PDMR	12,619	5,949	£7.625	19,561	0.022%

The exercise of the options was subject to the achievement of performance conditions which vested at 100% of the total award.

For further information, please contact:

Zoe Goulding, Company Secretary and Solicitor                 

Telephone number: 01606 814730

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSQKBDDPBKDNCD